ADAR and liver cancer: In liver cancer, ADAR1 overexpression and ADAR2 downregulation predict poor prognosis and increased risk of postoperative recurrence (Chan et al., 2014), an effect attributed to the differential selectivity in mRNA targeting by ADAR1/2.